Drugs that contain Tenofovir Alafenamide Fumarate
1. List of Vemlidy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(11 months ago) | |
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Aug 22, 2023 |
| New Patient Population (NPP) | Oct 17, 2025 |
Market Authorisation Date: 10 November, 2016
Treatment: Treatment of chronic hepatitis b in adult patients
Dosage: TABLET;ORAL
How can I launch a generic of VEMLIDY before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic